Brief: Mesoblast Says QTRLY Loss Attributable $24.5 Million
28/02/2023 01:28
Feb 28 (Reuters) - Mesoblast Ltd MSB.AX :
* QTRLY LOSS ATTRIBUTABLE $24.5 MILLION VERSUS LOSS $25.9
MILLION
* QTRLY REVENUE $2.1 MILLION VERSUS $2.4 MILLION
Source text for Eikon: ID:nASX9b5CBw
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M